Coluracetam
Systematic (IUPAC) name | |
---|---|
N-(2,3-Dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2-oxo-1-pyrrolidinyl)acetamide
|
|
Identifiers | |
CAS Number | 135463-81-9 |
ATC code | None |
PubChem | CID: 214346 |
ChemSpider | 185836 |
Chemical data | |
Formula | C19H23N3O3 |
Molecular mass | 341.404 g/mol |
|
|
|
Coluracetam (INN) (code name BCI-540; formerly MKC-231) is a nootropic agent of the racetam family.[1] It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer's disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a "Qualifying Therapeutic Discovery Program Grant" by the state of California.[2] Findings from phase IIa clinical trials have suggested that it would be a potential medication for comorbid MDD with generalized anxiety disorder (GAD).[3] BrainCells Inc is currently[when?] out-licensing the drug for this purpose.[4][full citation needed] It may also have potential use in prevention and treatment of ischemic retinopathy and retinal and optic nerve injury.[medical citation needed]
Coluracetam has been shown to reverse the loss of choline acetyltransferase production in the medial septal nucleus of rats exposed to phencyclidine (PCP), and is considered a potential therapeutic drug for schizophrenia.[5]
Mechanism of action
Coluracetam enhances high-affinity choline uptake (HACU),[6] which is the rate-limiting step of acetylcholine (ACh) synthesis. Studies have shown coluracetam to improve learning impairment on a single oral dose given to rats which have been exposed to cholinergic neurotoxins. Subsequent studies have shown that it may induce long-lasting procognitive effects in cholinergic neurotoxin-treated rats by changing the choline transporter regulation system.[7]
See also
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Qualifying Therapeutic Discovery Project Grants for the State of California, IRS.gov.
- ↑ BrainCells Inc. Announces Results From Exploratory Phase 2a Trial of BCI-540 Archived November 21, 2011 at the Wayback Machine
- ↑ [Pipeline,BCI-540], BCI-540 (coluracetam).
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Vague or ambiguous time from January 2015
- Articles with unsourced statements from January 2015
- Racetams
- Acetamides
- Furans
- Pyrrolidones
- Nootropics